ALK NSCLC

Conference Insider

Lorlatinib Superior To Crizotinib in ALK+ NSCLC

10/29/2021

Results from a subgroup analyses of the CROWN trial found first-line lorlatinib offered greater PFS benefit to crizotinib in Asian patients with ALK+ NSCLC.

Results from a subgroup analyses...

10/29/2021

Oncology

Conference Coverage

Real-World Data Shows Crizotinib is Effective Treating in ALK+ and ROS1+ NSCLC

10/27/2021

French patients with advanced NSCLC with ALK-positive or ROS1-positive gene rearrangement responded well to Crizotinib, according to real-world data presented at the 2021 ESMO Congress.

French patients with advanced...

10/27/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment is Superior in ALK+ NSCLC?

10/15/2021

True or false: Recent data from the ESMO Congress confirm crizotinib showed greater efficacy than brigatinib for patients with ALK TKI-naïve advanced ALK+ NSCLC.

True or false: Recent data from...

10/15/2021

Oncology

Test Your Knowledge

Quiz: Which of the Following is Not a Viable TKI for ALK+ NSCLC?

10/15/2021

Multiple choice: Which of the following is not a viable TKI to use after brigatinib discontinuation for patients with ALK+ NSCLC?

Multiple choice: Which of the...

10/15/2021

Oncology

Conference Coverage

Brigatinib Superior to Crizotinib in ALK NSCLC

09/22/2021

Final results from the ALTA-1L trial found that brigatinib demonstrated greater survival benefit than crizotinib in patients with ALK+ NSCLC.

Final results from the ALTA-1L...

09/22/2021

Oncology

Conference Coverage

Brigatinib Yields Durable Benefit in ALK NSCLC

09/22/2021

In a recent study in ALK+ NSCLC, post-brigatinib statuses and TKI therapy was investigated to understand the clinical effects of brigatinib after treatment discontinuation.

In a recent study in ALK+ NSCLC,...

09/22/2021

Oncology

Conference Insider

Later Generation ALK Inhibitors Yield Encouraging Results in NSCLC

06/15/2021

According to results from a retrospective study presented at the virtual 2021 ASCO Annual Meeting, newer generations of ALK inhibitors demonstrated improved survival and blood-brain barrier penetration in NSCLC with brain metastases.

According to results from a...

06/15/2021

Oncology

Conference Insider

Brigatinib Safe, Effective for Crizotinib-Refractory ALK+ NSCLC

06/03/2021

Findings from the ALTA trials show that brigatinib is effective, with manageable safety, in patients with crizotinib-refractory ALK+ NSCLC.

Findings from the ALTA trials...

06/03/2021

Oncology

Conference Insider

No Survival Benefit With Alectinib vs Crizotinib for ALK+ NSCLC